Taking into account this rationale we investigated whether Φ‐NGAL macrophage cell therapy could overcome the limitations of BM‐ΦM2 and halt the progression of DKD as infused Φ‐NGAL macrophages reach the diabetic kidney. Here, LCN2 is linked to diabetic kidney disease.